GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) reported Q1 2022 net revenues of $55.2 million, a 41% year-over-year increase, driven by the Oxbryta launch for children aged 4 to <12 years. The company reinitiated the GBT601 Phase 1 trial and aims to start the Phase 2/3 trial mid-2022. Oxbryta sales saw a slight 2% sequential decline, attributed to inventory adjustments. GBT has received marketing authorization in the EU and anticipates a UK approval by mid-2022. The net loss for the quarter was $81.4 million, up from $74.9 million in Q1 2021.

Global Blood Therapeutics (GBT) announced it will report its first quarter 2022 financial results on May 4, 2022, after U.S. market close. A conference call will take place the same day at 4:30 p.m. ET to discuss these results and provide a business update. GBT focuses on developing treatments for sickle cell disease (SCD), highlighted by its FDA-approved drug Oxbryta. The company is also advancing its pipeline with a Phase 3 program for inclacumab and continues to explore new therapeutic targets.

Global Blood Therapeutics (GBT) announced the grant of 64,050 restricted stock units to 21 new employees on April 1, 2022. This award is part of the Amended and Restated 2017 Inducement Equity Plan and serves as an inducement for employees joining the company, aligning with NASDAQ Listing Rule 5635(c)(4). GBT is committed to advancing treatments for sickle cell disease (SCD) and has introduced Oxbryta, the first FDA-approved treatment targeting hemoglobin polymerization in SCD. The company is also progressing with additional programs in SCD, including inclacumab and GBT021601.

Global Blood Therapeutics, Inc. (GBT) announced its participation in a virtual fireside chat during the Guggenheim Genomic Medicines & Rare Disease Day on April 1, 2022, at 12:00 p.m. E.T. The chat will be accessible via live webcast on GBT's website, with a replay available for one month. GBT is focused on developing treatments for sickle cell disease (SCD), having introduced Oxbryta (voxelotor), the first FDA-approved medicine targeting the root cause of SCD. The company is also advancing its pipeline, including a Phase 3 program for inclacumab and GBT021601, aimed at improving SCD management.

Global Blood Therapeutics (GBT) announced the allocation of restricted stock units (RSUs) to 19 new employees on March 1, 2022, totaling 42,380 shares. These awards were granted as an inducement for joining the company in compliance with NASDAQ Listing Rule 5635(c)(4). The RSUs are part of GBT's Amended and Restated 2017 Inducement Equity Plan, designed to attract talent in the biopharmaceutical sector. GBT focuses on developing treatments for sickle cell disease, including the FDA-approved Oxbryta and an advancing pipeline of therapies.

The GBT Foundation is now accepting proposals for the Access to Care Empowerment (ACE) Grant Program, which will fund community-based organizations focused on sickle cell disease (SCD). Up to five grants of $50,000 each will be awarded, with proposals accepted until April 22, 2022. This new program separates funding initiatives previously included in the ACCEL Grant Program. GBT Foundation aims to enhance sustainable healthcare access for SCD patients through these grants.

Global Blood Therapeutics (GBT) announced its participation in virtual investor conferences on March 7 and March 16, 2022. CEO Ted W. Love will engage in a panel discussion on non-malignant hematology at the Cowen 42nd Annual Health Care Conference. Both events will be webcast live on GBT’s website, with replays available for one month.

GBT focuses on developing treatments for sickle cell disease (SCD), including Oxbryta®, the first FDA-approved treatment targeting the root cause of SCD.

Global Blood Therapeutics (GBT) reported Q4 2021 net revenues of $56.1 million, a 36% year-over-year increase, contributing to full-year revenues of $194.7 million, a 57% increase. Key developments include FDA approvals for Oxbryta, expanding its patient base and achieving broad payer coverage. The company holds a strong cash position of $734.8 million. However, GBT recorded a net loss of $87.6 million for Q4 2021, up from $61.8 million in Q4 2020. Management remains optimistic about overcoming COVID-19 impacts and anticipates improving prescription rates.